Spiramycin III
| Code | Size | Price |
|---|
| TAR-T26206-5mg | 5mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Spiramycin III is an antibiotic within the erythromycin/carbomycin group of compounds.
CAS:
24916-52-7
Formula:
C46H78N2O15
Molecular Weight:
899.129
Purity:
0.98
SMILES:
CCC(=O)O[C@@H]1CC(=O)O[C@H](C)CC=C/C=C/[C@H](O[C@H]2CC[C@@H]([C@H](C)O2)N(C)C)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@@H]([C@H]2O)N(C)C)[C@H]1OC
References
1. Deng Y, Ju Y, Lu Z, Lu F, Yan D, Bie X. Identification of 4?-isovaleryl-spiramycin III produced by Bacillus sp. fmbJ. Arch Microbiol. 2014 Feb;196(2):87-95. doi: 10.1007/s00203-013-0939-x. Epub 2013 Dec 20. PubMed PMID: 24356910.
2. Liu L, Saevels J, Louis P, Nelis H, Rico S, Dierick K, Guyomard S, Roets E, Hoogmartens J. Interlaboratory study comparing the microbiological potency of spiramycins I, II and III. J Pharm Biomed Anal. 1999 Jun;20(1-2):217-24. PubMed PMID: 10704026.
3. Ramu K, Shringarpure S, Cooperwood S, Beale JM, Williams JS. 1H-NMR and 13C-NMR spectral assignments of spiramycins I and III. Pharm Res. 1994 Mar;11(3):458-65. PubMed PMID: 8008717.
4. Li Z, Hu F, Ye R, Lv H, Zeng J. Influence of Al(3+) on the titer of spiramycin and effective components in fermentor. Prep Biochem Biotechnol. 2017 May 28;47(5):481-488. doi: 10.1080/10826068.2017.1292290. Epub 2017 Feb 17. PubMed PMID: 28278108.